ReviewFrontiers in public health2022
Wearable Walking Assistant for Freezing of Gait With Environmental IoT Monitoring: A Contribution to the Discussion.
Review in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Exploring the therapeutic potential of Astragalin in Parkinson's disease: a network pharmacology approach.Annals of medicine and surgery (2012) · 2026Article
- Gait Characteristics Analyzed with Smartphone IMU Sensors in Subjects with Parkinsonism under the Conditions of "Dry" Immersion.Sensors (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease, significantly increasing in the last three decades. Worldwide, seven to ten million people are affected by PD. In people living with PD, freezing of gait (FoG) significantly impacts activities of daily living, potentially leading to falls, injuries, and loss of autonomy. FoG prevalence rates vary widely, reaching at least 50% of patients with PD. Current therapeutic options have limited effectiveness, and their complement with innovative technology-based solutions in the real world is demanded to enhance daily functioning for people living with PD. This article provides a narrative review of current technological developments for people living with PD and, derived from that evidence, presents a perspective on integrating wearable technology and IoT to support telemonitoring and self-management of people living with PD in their daily living environment. Complementing current therapeutic options with technology-based solutions in PD patients' real-world environment is crucial to enhancing the quality of life of people living with PD. In that way, wearable technology and IoT might constitute resources of excellence in seamless monitoring and self-management in people's home environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.